Actively Recruiting
Comparing Doxorubicin With or Without Pembrolizumab for Treatment of Aggressive Metastatic or Unresectable Sarcomas
Led by National Cancer Institute (NCI) · Updated on 2026-10-26
365
Participants Needed
269
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying patients with metastatic or unresectable dedifferentiated liposarcoma DDLPS, undifferentiated pleomorphic sarcoma UPS, or related poorly differentiated sarcomas to compare the effects of combining immunotherapy pembrolizumab with chemotherapy doxorubicin versus chemotherapy alone. The goal is to see if adding pembrolizumab helps patients live longer without their disease worsening. This is a phase III randomized trial focusing on treatment outcomes and safety. Participants are randomly assigned to one of two groups. One group receives doxorubicin intravenously every 21 days for six cycles along with pembrolizumab intravenously every 21 days for up to two years, provided there is no disease progression or unacceptable side effects. The other group receives only doxorubicin for six cycles and may receive pembrolizumab alone after disease progression, also given every 21 days for up to two years. Throughout the study, patients undergo heart function assessments ECHO or MUGA scans, standard imaging scans, and blood sample collections. During the trial, patients are monitored closely with scans and blood tests to assess disease progression and treatment effects. After completing treatment, follow-up visits occur every three months for two years and then every six months up to ten years. The main measure is progression-free survival, tracking the time until disease progression or death. Overall survival and response rates are also evaluated. Safety and tolerability are monitored throughout the study.
CONDITIONS
Brief Title
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here